Mandalay Resources Corporation Announces Pricing of Public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
37
Mandalay Resources Corporation Announces Pricing of Public Offering of Subscription Receipts

Not for distribution to U.S. news wire services or dissemination in the United States.

TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) announced today that, in connection with its previously announced public offering of subscription receipts (“Subscription Receipts”), it has entered into an underwriting agreement with a syndicate of underwriters led by BMO Capital Markets and including CIBC Capital Markets and HSBC Securities (Canada) Inc. (the “Underwriters”) to sell 358,400,000 Subscription Receipts at a price of C$0.12 per Subscription Receipt (the “Offering Price”) for gross proceeds to the Company of approximately C$43 million (the “Public Offering”). The Company has granted the Underwriters an option, exercisable at the Offering Price for a period of 30 days following the closing of the Public Offering, to purchase up to an additional 53,760,000 Subscription Receipts to cover over-allotments, if any (the “Over-Allotment Option”).

The net proceeds of the Public Offering, along with the net proceeds of a US$8 million convertible bridge loan that an affiliate of CE Mining Fund III L.P. (“CE Mining”) has agreed to advance to the Company, subject to the satisfaction of certain conditions and concurrently with the completion of the Public Offering, will be used by Mandalay to fund working capital requirements (including development work at Costerfield, and tailings upgrade and capital requirements at Björkdal), debt reduction (including establishing a cash reserve for the purposes of satisfying the Company’s obligations in respect of its Gold Bonds, future planned exploration activities at high potential opportunities including at Costerfield (Youle lode and deeper hole targets) as well as the emerging Aurora Zone at Björkdal, and for general corporate purposes.

Each Subscription Receipt will entitle the holder thereof to receive one common share of the Company (a “Common Share”), subject to adjustment in certain circumstances.

The Subscription Receipts will be issued pursuant to a subscription receipt agreement to be entered into upon the completion of the Public Offering, pursuant to which the gross proceeds of the Public Offering less 50% of the underwriters’ commission payable in connection with the Public Offering (the “Escrowed Proceeds”), will be held in escrow in an interest-bearing account. Upon satisfaction or waiver of certain escrow release conditions (the “Escrow Release Conditions”), including the receipt of all shareholder approvals required for the Public Offering, the remaining 50% of the underwriters’ commission and the underwriters’ expenses will be released to the underwriters, the remaining Escrowed Proceeds will be released to the Company and each Subscription Receipt will be exchanged for one Common Share.

If the Escrow Release Conditions are not satisfied by April 30, 2019, holders of the Subscription Receipts will receive an amount per Subscription Receipt equal to the offering price per Subscription Receipt (the “Offering Price”) together with a pro-rata share of any interest earned on the Escrowed Proceeds. If the Escrowed Proceeds (plus accrued interest) are not sufficient to make such payment, the Company will contribute such amounts as are necessary to satisfy any shortfall.

The Public Offering is expected to close on or about February 20, 2019 and is subject to certain conditions, including Mandalay receiving all necessary regulatory approvals and Mandalay’s receipt of the bridge loan.

For further information regarding the Public Offering and the CE Mining bridge loan, please refer to the Company’s news release dated February 11, 2019 and a prospectus supplement to be filed under Mandalay’s final short form base prospectus dated February 12, 2018 in respect of the Public Offering, a copy of which will be available under the Company’s profile on SEDAR at www.sedar.com.

The securities offered under the Public Offering have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For Further Information:

Dominic Duffy President and Chief Executive Officer

Greg DiTomaso Director of Investor Relations

647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on growing production at its gold and antimony operation in Australia, and gold production from its operation in Sweden to generate near term cash flow.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the proposed Financing, Mandalay’s current and anticipated financial condition and Mandalay’s expected future production and exploration results. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. There can be no assurance that the Financing will be completed on the terms described in this press release or at all or that Mandalay will be able to continue to operate as a going concern if the Financing is not completed. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading “Risk Factors” in Mandalay’s annual information form dated March 29, 2018, a copy of which is available under Mandalay’s profile at www.sedar.com and in the prospectus supplement to be filed by Mandalay in connection with the Public Offering. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading